Update on the Use of Biologics in Vasculitides

Author(s): Sahana Vishwanath, Manisha Relan, Long Shen, Julian L. Ambrus Jr.

Journal Name: Current Pharmaceutical Biotechnology

Volume 15 , Issue 6 , 2014


Become EABM
Become Reviewer
Call for Editor

Abstract:

Vasculitides are disease in which injury to blood vessels leads to various degrees and types of organ dysfunction. They are subdivided into different groups dependent on the size of blood vessels involved as well as other particular clinical features. Therapy is dependent upon the size of the blood vessels involved and the nature of the disease. For medium and large vessel vasculitides, glucocorticoids, cyclophosphamide, azathioprine and methotrexate have been the mainstay for induction and maintenance of remission. Because of potential for side effects from standard therapies, various biologic agents have been evaluated in the treatment of ANCA positive vasculitis (AAV), cryoglobulinemic vasculitis, Behcet’s disease and Takayasu’s Arteritis (TAK). In this article, we present a review on biologic agents used in various vasculitides.

Keywords: Behcet's disease, biologics, takayasu arteritis, vasculitis.granulomatous polyangiitis.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 6
Year: 2014
Published on: 10 September, 2014
Page: [558 - 562]
Pages: 5
DOI: 10.2174/138920101506140910151126
Price: $65

Article Metrics

PDF: 37